Skip to main content

Alpha1H: A Unique Bladder Cancer Therapeutic, Acting with Great Precision

Project description

Novel highly efficient bladder cancer treatment with low toxicity

The ideal cancer treatment should combine great efficacy with high selectivity. The Swedish HAMLET Pharma AB develops revolutionary cancer treatments on a peptide-based platform for targeting and killing tumor cells with high precision. Their proprietary drug complex is derived from the human breast milk protein, alpha-lactalbumin, and represents a therapeutic solution with high tumor-killing capacity, high target specificity, no demonstrated toxicity, killing more than 40 different types of tumor cells. The EU-funded HAMLET-BC project will advance this drug complex in combination with the synthetic drug candidate Alpha1H into the clinical development pipeline as an early-stage treatment for bladder cancer, which has the highest recurrence rate among all cancer types.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-EIC-SMEInst-2018-2020-3

Coordinator

HAMLET PHARMA AB
Net EU contribution
€ 1 995 165,43
Address
Klinikgatan 32
222 42 Lund
Sweden

See on map

Region
Södra Sverige Sydsverige Skåne län
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 855 070,91

Participants (1)

Third-party

Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.

LINNANE PHARMA AB
Sweden
Net EU contribution
€ 201 979,16
Address
Slottsgatan 32
211 33 Malmo

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Södra Sverige Sydsverige Skåne län
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 86 562,50